INT 2228
Alternative Names: INT-2228Latest Information Update: 10 Nov 2023
At a glance
- Originator Intercept Pharmaceuticals
- Class Anti-inflammatories; Antifibrotics; Bile acids and salts; Hepatoprotectants
- Mechanism of Action Farnesoid X-activated receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Hepatic fibrosis; Non-alcoholic steatohepatitis
Most Recent Events
- 08 Nov 2023 Intercept Pharmaceuticals has been acquired by Alfasigma
- 24 Jan 2022 Pharmacodynamics data from preclinical studies in Hepatic fibrosis presented at the 72nd Annual Meeting of the American Association for the Study of Liver Diseases (AASLD-2021)
- 12 Nov 2021 Preclinical trials in Hepatic fibrosis in USA (unspecified route)